Skip to main content
Top
Published in: International Urogynecology Journal 3/2007

01-03-2007 | Current Opinion/Update

Bias in research and conflict of interest: why should we care?

Author: H. P. Dietz

Published in: International Urogynecology Journal | Issue 3/2007

Login to get access

Excerpt

Medical journals are a prime source of professional information for doctors and have a major impact on patient care. Editors and authors are, even more so than the practising clinician, trustees of the public good. Our role is to provide information that is as ‘true’ as we can make it. To this purpose, it is imperative that bias in published research be reduced as far as possible. In fact, “the entire infrastructure of science [...] is built on the fundamental notion of eliminating, or at least controlling for, [...] bias” [1]. In therapeutic medicine, the double-blind multicentre randomised controlled trial (RCT) is seen as the ‘gold standard’ of bias reduction—developed in response to higher scientific and regulatory standards and to fulfil the precepts of evidence-based medicine. …
Literature
1.
go back to reference Coyle SL (2002) Ethics, Human Rights Committee ACoP-A. Physician-industry relations. Part 1: individual physicians. Ann Intern Med 136(5):396–402PubMed Coyle SL (2002) Ethics, Human Rights Committee ACoP-A. Physician-industry relations. Part 1: individual physicians. Ann Intern Med 136(5):396–402PubMed
2.
go back to reference Korn DMD (2002) Industry, academia, investigator: managing the relationships. Acad Med 77(11):1089–1095 (November)PubMedCrossRef Korn DMD (2002) Industry, academia, investigator: managing the relationships. Acad Med 77(11):1089–1095 (November)PubMedCrossRef
3.
go back to reference Mathews W (2005) A ghost story: at medical journals, writers paid by industry play big role. Wall Street J A1 (Dec 13) Mathews W (2005) A ghost story: at medical journals, writers paid by industry play big role. Wall Street J A1 (Dec 13)
4.
5.
go back to reference Bhandari M, Busse JW, Jackowski D et al (2004) Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials (see comment). CMAJ Can Med Assoc J 170(4):477–480 Bhandari M, Busse JW, Jackowski D et al (2004) Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials (see comment). CMAJ Can Med Assoc J 170(4):477–480
6.
go back to reference Montgomery JH, Byerly M, Carmody T et al (2004) An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials 25(6):598–612PubMedCrossRef Montgomery JH, Byerly M, Carmody T et al (2004) An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia. Control Clin Trials 25(6):598–612PubMedCrossRef
7.
go back to reference Buchkowsky SS, Jewesson PJ (2004) Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 38(4):579–585PubMedCrossRef Buchkowsky SS, Jewesson PJ (2004) Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother 38(4):579–585PubMedCrossRef
8.
go back to reference Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA (2005) Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatr 162(10):1957–1960PubMedCrossRef Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA (2005) Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatr 162(10):1957–1960PubMedCrossRef
9.
go back to reference Goetzsche P (2005) Research integrity and pharmaceutical industry sponsorship. Med J Aust 182(11):549 Goetzsche P (2005) Research integrity and pharmaceutical industry sponsorship. Med J Aust 182(11):549
10.
go back to reference Gibbons R, Landry F, Blouch D et al (1998) A comparison of physicians’ and patients’ attitudes toward pharmaceutical industry gifts. J Gen Intern Med 13:151–154PubMedCrossRef Gibbons R, Landry F, Blouch D et al (1998) A comparison of physicians’ and patients’ attitudes toward pharmaceutical industry gifts. J Gen Intern Med 13:151–154PubMedCrossRef
11.
go back to reference Rogers W, Mansfield P, Braunack-Mayer A, Jureidini J (2004) The ethics of pharmaceutical industry relationships with students. Med J Aust 180:411–414PubMed Rogers W, Mansfield P, Braunack-Mayer A, Jureidini J (2004) The ethics of pharmaceutical industry relationships with students. Med J Aust 180:411–414PubMed
12.
go back to reference Andersen NV (2006) Gunnar lose vs. Yamanouchi. Ugeskrift for Laeger 168(6):546 Andersen NV (2006) Gunnar lose vs. Yamanouchi. Ugeskrift for Laeger 168(6):546
13.
go back to reference Brown AJ (2001) Therapeutic uses of vitamin D analogues. Am J Kidney Dis 38(Suppl 5):S3–S19PubMed Brown AJ (2001) Therapeutic uses of vitamin D analogues. Am J Kidney Dis 38(Suppl 5):S3–S19PubMed
14.
go back to reference Choudhry NK, Stelfox HT, Detsky AS (2002) Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287(5):612–617PubMedCrossRef Choudhry NK, Stelfox HT, Detsky AS (2002) Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287(5):612–617PubMedCrossRef
15.
go back to reference Moynihan R (2003) The making of a disease: female sexual dysfunction. Br Med J 326:45–47CrossRef Moynihan R (2003) The making of a disease: female sexual dysfunction. Br Med J 326:45–47CrossRef
16.
go back to reference Moynihan R, Cassels A (2005) Selling sickness: how drug companies are turning us all into patients. G. Allen, Sydney, Australia Moynihan R, Cassels A (2005) Selling sickness: how drug companies are turning us all into patients. G. Allen, Sydney, Australia
17.
go back to reference N.N. World Association of Medical Editors Recommendations on Publication Ethics Policies for Medical Journals, 2006 at: http://www.wame.org/, accessed 15.5.06 N.N. World Association of Medical Editors Recommendations on Publication Ethics Policies for Medical Journals, 2006 at: http://​www.​wame.​org/​, accessed 15.5.06
18.
go back to reference N.N. Uniform Requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication: International Committee of Medical Journal Editors, 2006, at: http://www.icmje.org/, accessed 15.5.06 N.N. Uniform Requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication: International Committee of Medical Journal Editors, 2006, at: http://​www.​icmje.​org/​, accessed 15.5.06
19.
go back to reference Korn, D. and S. Ehringhaus, Principles for strengthening the integrity of clinical research. 2006, Public Library of Science at: http://www.plosclinicaltrials.org Korn, D. and S. Ehringhaus, Principles for strengthening the integrity of clinical research. 2006, Public Library of Science at: http://​www.​plosclinicaltria​ls.​org
20.
go back to reference N.N. World Medical Association Declaration of Helsinki, 2004, at: http://www.wma.net/e/policy/b3.htm., accessed 15.5.06 N.N. World Medical Association Declaration of Helsinki, 2004, at: http://​www.​wma.​net/​e/​policy/​b3.​htm.​, accessed 15.5.06
21.
go back to reference 4th Annual Patient Recruitment for Clinical Trials. 2006: New York, at: www.marcusevansbb.com/recruitment, accessed 10.6.06 4th Annual Patient Recruitment for Clinical Trials. 2006: New York, at: www.marcusevansbb.com/recruitment, accessed 10.6.06
22.
go back to reference The Allhat Officers and Coordinators for the Allhat Collaborative Research Group. Major outcomes in High-Risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA, 2002(Dec 18): p. 2981CrossRef The Allhat Officers and Coordinators for the Allhat Collaborative Research Group. Major outcomes in High-Risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA, 2002(Dec 18): p. 2981CrossRef
23.
go back to reference Liebermann J, Stroup T, McEvoy J et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209–23CrossRef Liebermann J, Stroup T, McEvoy J et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209–23CrossRef
24.
go back to reference Angell M (2004) The truth about the drug companies: how they deceive us and what to do about it. Random House, New York Angell M (2004) The truth about the drug companies: how they deceive us and what to do about it. Random House, New York
25.
go back to reference Curfman G, Morrissey S, Drazen J (2006) Expression of concern reaffirmed. N Engl J Med 354(11):1193PubMedCrossRef Curfman G, Morrissey S, Drazen J (2006) Expression of concern reaffirmed. N Engl J Med 354(11):1193PubMedCrossRef
26.
go back to reference Moynihan R (2002) Alosetron: a case study in regulatory capture, or a victory for patients’ rights? Br Med J 325:592–595CrossRef Moynihan R (2002) Alosetron: a case study in regulatory capture, or a victory for patients’ rights? Br Med J 325:592–595CrossRef
27.
go back to reference Lievre M (2002) Alosetron for irritable bowel syndrome. Br Med J 325:555–556CrossRef Lievre M (2002) Alosetron for irritable bowel syndrome. Br Med J 325:555–556CrossRef
28.
29.
go back to reference Fontanarosa PB, Flanagin A, DeAngelis CD (2005) Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies. JAMA 294:110–111 (July 6)PubMedCrossRef Fontanarosa PB, Flanagin A, DeAngelis CD (2005) Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies. JAMA 294:110–111 (July 6)PubMedCrossRef
1.
go back to reference Kassirer JP (2005) On the take. Oxford University Press, New York Kassirer JP (2005) On the take. Oxford University Press, New York
2.
go back to reference Krimsky S (2003) Science in the private interest. Rowman & Littlefield, Lanham, MD Krimsky S (2003) Science in the private interest. Rowman & Littlefield, Lanham, MD
3.
go back to reference Angell M (2004) The truth about the drug companies: how they deceive us and what to do about it. Random House, New York Angell M (2004) The truth about the drug companies: how they deceive us and what to do about it. Random House, New York
4.
go back to reference Moynihan R, Cassels A (2005) Selling sickness: how drug companies turning us all into patients. G. Allen, Sydney Moynihan R, Cassels A (2005) Selling sickness: how drug companies turning us all into patients. G. Allen, Sydney
Metadata
Title
Bias in research and conflict of interest: why should we care?
Author
H. P. Dietz
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
International Urogynecology Journal / Issue 3/2007
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-006-0236-1

Other articles of this Issue 3/2007

International Urogynecology Journal 3/2007 Go to the issue